AngioDynamics, Inc. Appoints Karen Licitra as a Class III Director and to Compensation Committee
July 19, 2019 at 04:20 pm
Share
On July 17, 2019, the board of directors of AngioDynamics, Inc. appointed Karen Licitra as a Class III director of AngioDynamics, effective immediately.
Ms. Licitra was appointed to the Compensation Committee of the board of directors. From January 2014 through August 2015, Ms. Licitra served as Corporate Vice President, Worldwide Government Affairs & Policy at Johnson & Johnson. From December 2011 to December 2013, Ms. Licitra served as the Worldwide Chairman, Global Medical Solutions at Johnson & Johnson. From July 2002 to November 2011, she served as the Company Group Chairman and Worldwide Franchise Chairman at Ethicon Endo-Surgery, Inc., a Johnson & Johnson medical device company. Ms. Licitra was appointed to the Compensation Committee of the board of directors. AngioDynamics’ board of directors has determined that Ms. Licitra is independent under the Nasdaq listing standards.
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.
ANGIODYNAMICS, INC. 
